

# Michelle M Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1228788/publications.pdf>

Version: 2024-02-01

45  
papers

1,639  
citations

471509

17  
h-index

302126

39  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2569  
citing authors

#	ARTICLE	IF	CITATIONS
1	Back to the Future: Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 30-34.	0.8	1
2	Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2022, 12, 265-282.	2.1	90
3	Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas. <i>Neuroscience Informatics</i> , 2022, , 100088.	4.5	0
4	Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	1.2	14
5	Radiation-Induced Imaging Changes and Cerebral Edema following Stereotactic Radiosurgery for Brain AVMs. <i>American Journal of Neuroradiology</i> , 2021, 42, 82-87.	2.4	15
6	Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1537-1546.	1.2	12
7	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	1.2	75
8	Reducing Radiation-Induced Cognitive Toxicity: Sparing the Hippocampus and Beyond. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1131-1136.	0.8	6
9	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 792-803.	0.8	23
10	Survival Prediction Analysis in Glioblastoma With Diffusion Kurtosis Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 690036.	2.8	2
11	Individualizing Therapy for Malignant Gliomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 335-336.	2.0	0
12	Precision Radiotherapy for Gliomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 353-363.	2.0	3
13	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	2.8	7
14	Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. <i>Advances in Radiation Oncology</i> , 2020, 5, 53-61.	1.2	11
15	Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning. <i>Scientific Reports</i> , 2020, 10, 20331.	3.3	36
16	Stereotactic Radiosurgery for Brain Arteriovenous Malformations: Evaluation of Obliteration and Review of Associated Predictors. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104863.	1.6	23
17	BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 478-486.	0.8	6
18	Microstructure Modeling of High b-Value Diffusion-Weighted Images in Glioblastoma. <i>Tomography</i> , 2020, 6, 34-43.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Generation of Synthetic CT Images From MRI for Treatment Planning and Patient Positioning Using a 3-Channel U-Net Trained on Sagittal Images. <i>Frontiers in Oncology</i> , 2019, 9, 964.	2.8	41
20	Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2019, 86, E164-E172.	1.1	5
21	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	1.2	17
22	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	2.9	11
23	Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging Registration to Delineate the Spinal Cord During Spine Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2019, 122, e655-e666.	1.3	8
24	Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. <i>Practical Radiation Oncology</i> , 2019, 9, e22-e28.	2.1	8
25	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	1.2	139
26	Developing a Pipeline for Multiparametric MRI-Guided Radiation Therapy: Initial Results from a Phase II Clinical Trial in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2019, 5, 118-126.	1.8	22
27	Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 155-162.	2.9	4
28	A Primer on Secondary Brain Neoplasms: The Essentials. <i>Seminars in Roentgenology</i> , 2018, 53, 101-111.	0.6	2
29	Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 757-764.	0.8	16
30	No patient left behind: The promise of immune priming with epigenetic agents. <i>Oncolmmunology</i> , 2017, 6, e1315486.	4.6	11
31	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
32	Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma. <i>Oncotarget</i> , 2017, 8, 112992-113001.	1.8	21
33	Tumor image signatures and habitats: a processing pipeline of multimodality metabolic and physiological images. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	1.5	3
34	Turning on the Radio: Epigenetic Inhibitors as Potential Radioprimering Agents. <i>Biomolecules</i> , 2016, 6, 32.	4.0	9
35	Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 455-456.	1.2	11
36	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. <i>Translational Oncology</i> , 2016, 9, 108-113.	3.7	28

#	ARTICLE	IF	CITATIONS
37	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	1.2	566
38	Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 696-705.	0.8	29
39	Non-invasive metabolic imaging of brain tumours in the era of precision medicine. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 725-739.	27.6	88
40	RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. <i>Case Reports in Oncology</i> , 2016, 9, 171-176.	0.7	11
41	Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 305-311.	0.8	18
42	Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 811-819.	0.8	41
43	NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. <i>Redox Biology</i> , 2015, 6, 1-8.	9.0	98
44	Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma. <i>Seminars in Radiation Oncology</i> , 2015, 25, 172-180.	2.2	6
45	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	10.7	76